- Home
- Publications
- Publication Search
- Publication Details
Title
Current therapies for lowering lipoprotein (a)
Authors
Keywords
-
Journal
JOURNAL OF LIPID RESEARCH
Volume 57, Issue 9, Pages 1612-1618
Publisher
American Society for Biochemistry & Molecular Biology (ASBMB)
Online
2015-12-05
DOI
10.1194/jlr.r053066
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Results of Bococizumab, A Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, from a Randomized, Placebo-Controlled, Dose-Ranging Study in Statin-Treated Subjects With Hypercholesterolemia
- (2015) Christie M. Ballantyne et al. AMERICAN JOURNAL OF CARDIOLOGY
- Effects of Extended-Release Nicotinic Acid on Apolipoprotein (a) Kinetics in Hypertriglyceridemic PatientsSignificance
- (2015) Mikaël Croyal et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Mipomersen, an Antisense Oligonucleotide to Apolipoprotein B-100, Reduces Lipoprotein(a) in Various Populations With HypercholesterolemiaSignificance
- (2015) Raul D. Santos et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Lipoprotein(a) Catabolism Is Regulated by Proprotein Convertase Subtilisin/Kexin Type 9 through the Low Density Lipoprotein Receptor
- (2015) Rocco Romagnuolo et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans
- (2015) Nike Müller et al. JOURNAL OF LIPID RESEARCH
- Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis
- (2015) Romain Capoulade et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial
- (2015) G Kees Hovingh et al. LANCET
- Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial
- (2015) Frederick J Raal et al. LANCET
- Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study
- (2015) Sotirios Tsimikas et al. LANCET
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
- (2015) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Proprotein Convertase Subtilisin Kexin Type 9 Promotes Intestinal Overproduction of Triglyceride-Rich Apolipoprotein B Lipoproteins Through Both Low-Density Lipoprotein Receptor–Dependent and –Independent Mechanisms
- (2014) Shirya Rashid et al. CIRCULATION
- Dramatic lowering of very high Lp(a) in response to niacin
- (2014) Min Li et al. Journal of Clinical Lipidology
- Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance
- (2014) Erik Stroes et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)
- (2014) Frederick J. Raal et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cardiovascular prevention—end of the road for niacin?
- (2014) Sony Tuteja et al. Nature Reviews Endocrinology
- Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
- (2014) NEW ENGLAND JOURNAL OF MEDICINE
- Safety Profile of Extended-Release Niacin in the AIM-HIGH Trial
- (2014) Todd J. Anderson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prediction of Cardiovascular Events in Statin-Treated Stable Coronary Patients of the Treating to New Targets Randomized Controlled Trial by Lipid and Non-Lipid Biomarkers
- (2014) Benoit J. Arsenault et al. PLoS One
- Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study
- (2013) Iain B McInnes et al. ANNALS OF THE RHEUMATIC DISEASES
- Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia
- (2013) Evan A. Stein et al. CIRCULATION
- Lipoprotein Apheresis in Patients With Maximally Tolerated Lipid-Lowering Therapy, Lipoprotein(a)-Hyperlipoproteinemia, and Progressive Cardiovascular Disease
- (2013) Josef Leebmann et al. CIRCULATION
- Serum Proprotein Convertase Subtilisin/Kexin Type 9 and Cell Surface Low-Density Lipoprotein Receptor
- (2013) Hagai Tavori et al. CIRCULATION
- Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk
- (2013) Amit V. Khera et al. CIRCULATION
- New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs
- (2013) Giuseppe Danilo Norata et al. EUROPEAN HEART JOURNAL
- Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension
- (2013) Raul D. Santos et al. EUROPEAN HEART JOURNAL
- Lipoprotein(a): resurrected by genetics
- (2013) F. Kronenberg et al. JOURNAL OF INTERNAL MEDICINE
- Mipomersen, an Apolipoprotein B Synthesis Inhibitor, Reduces Atherogenic Lipoproteins in Patients With Severe Hypercholesterolemia at High Cardiovascular Risk
- (2013) Gregory S. Thomas et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Relationship of Apolipoproteins A-1 and B, and Lipoprotein(a) to Cardiovascular Outcomes
- (2013) John J. Albers et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effect of Nicotinic acid/Laropiprant in the lipoprotein(a) concentration with regard to baseline lipoprotein(a) concentration and LPA genotype
- (2013) Ana Cenarro et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Screening for and Management of Elevated Lp(a)
- (2013) Michael B. Boffa et al. Current Cardiology Reports
- Emerging therapeutic agents to lower lipoprotein (a) levels
- (2012) Brian Kolski et al. CURRENT OPINION IN LIPIDOLOGY
- Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial
- (2012) Maartje E. Visser et al. EUROPEAN HEART JOURNAL
- Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia
- (2012) Kiyohito Arai et al. JOURNAL OF LIPID RESEARCH
- Nicotinic acid inhibits hepaticAPOAgene expression: studies in humans and in transgenic mice
- (2012) Indumathi Chennamsetty et al. JOURNAL OF LIPID RESEARCH
- Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
- (2012) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or in Combination With Statins on HDL and LDL Cholesterol
- (2011) Stephen J. Nicholls et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists
- (2011) Michael H. Davidson et al. Journal of Clinical Lipidology
- Antisense Oligonucleotide Lowers Plasma Levels of Apolipoprotein (a) and Lipoprotein (a) in Transgenic Mice
- (2011) Esther Merki et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Lipoprotein(a) as a cardiovascular risk factor: current status
- (2010) Børge G. Nordestgaard et al. EUROPEAN HEART JOURNAL
- Management of Lp(a)
- (2010) W. Virgil Brown et al. Journal of Clinical Lipidology
- Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease
- (2010) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction
- (2009) Pia R. Kamstrup JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Relationship of Oxidized Phospholipids and Biomarkers of Oxidized Low-Density Lipoprotein With Cardiovascular Risk Factors, Inflammatory Biomarkers, and Effect of Statin Therapy in Patients With Acute Coronary Syndromes
- (2009) Alexander E. Fraley et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events
- (2009) Beate R Jaeger et al. Nature Reviews Cardiology
- Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
- (2009) Robert Clarke et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanism of Action of Niacin
- (2008) Vaijinath S. Kamanna et al. AMERICAN JOURNAL OF CARDIOLOGY
- Lipoprotein(a) Levels and Risk of Future Coronary Heart DiseaseLarge-Scale Prospective Data
- (2008) Anna Bennet ARCHIVES OF INTERNAL MEDICINE
- Relationship Between Biomarkers of Oxidized Low-Density Lipoprotein, Statin Therapy, Quantitative Coronary Angiography, and Atheroma Volume
- (2008) Seung Hyuk Choi et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia
- (2008) Frederick F Samaha et al. Nature clinical practice. Cardiovascular medicine
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now